Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYCLONE 3
2022-500461-28-06Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Abemaciclib combination arm with Placebo combination arm (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Planned start Sep 2022; status: authorised.
02
Drugs
abemaciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-500461-28-06.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500461-28-06.